Blinatumomab Consolidation Well Tolerated in MRD-Negative ALL

(MedPage Today) -- At the recent American Society of Hematology annual meeting, investigators presented a new analysis detailing toxicity outcomes of the E1910 trial--based on age, sex, body mass index, cytogenetic-molecular risk, and cycles...